Thrombosis and Haemostasis 2023 Editors' Choice Papers

This year's Editor's Choice highlights the 2023 publications in Thrombosis and Haemostasis (TH) and its open-access companion journal TH Open, focusing on manuscripts that have significantly resonated among our academic community. Unlike previous years since 2020, this year marks a notable shift, with coronavirus disease 2019 (COVID-19) papers no longer being in prime spotlight of TH publications. Instead, we have observed a trend toward integration of COVID-19 research within the broader context of cardiovascular studies.

Publication History

Article published online:
11 January 2024

• References

• 1 Galli M, Laborante R, Ortega-Paz L. et al. Factor XI inhibitors in early clinical trials: a meta-analysis. Thromb Haemost 2023; 123 (06) 576-584
• 2 Foulon-Pinto G, Lafuente-Lafuente C, Jourdi G. et al. Assessment of DOAC in GEriatrics (Adage Study): rivaroxaban/apixaban concentrations and thrombin generation profiles in NVAF very elderly patients. Thromb Haemost 2023; 123 (04) 402-414
• 3 Eikelboom JW, Weitz JI. Direct oral anticoagulants in the very elderly. Thromb Haemost 2023; 123 (04) 377-379
• 4 Grymonprez M, Petrovic M, De Backer TL, Steurbaut S, Lahousse L. The impact of polypharmacy on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Thromb Haemost 2023; (e-pub ahead of print). DOI: 10.1055/s-0043-1769735.
• 5 Zheng Y, Li S, Liu X, Lip GYH, Guo L, Zhu W. Effect of oral anticoagulants in atrial fibrillation patients with polypharmacy: a meta-analysis. Thromb Haemost 2023; (e-pub ahead of print). DOI: 10.1055/s-0043-1769735.
• 6 Romiti GF, Proietti M, Bonini N. et al; GLORIA-AF Investigators. Clinical complexity domains, anticoagulation, and outcomes in patients with atrial fibrillation: a report from the GLORIA-AF registry phase II and III. Thromb Haemost 2022; 122 (12) 2030-2041
• 7 Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol 2017; 14 (11) 627-628
• 8 Romiti GF, Pastori D, Rivera-Caravaca JM. et al. Adherence to the ‘Atrial Fibrillation Better Care’ pathway in patients with atrial fibrillation: impact on clinical outcomes-a systematic review and meta-analysis of 285,000 patients. Thromb Haemost 2022; 122 (03) 406-414
• 9 Romiti GF, Guo Y, Corica B, Proietti M, Zhang H, Lip GYH. mAF-App II trial investigators. Mobile health-technology-integrated care for atrial fibrillation: a win ratio analysis from the mAFA-II randomized clinical trial. Thromb Haemost 2023; 123 (11) 1042-1048
• 10 Corica B, Romiti GF, Proietti M. NOACs in atrial fibrillation patients with polypharmacy. Thromb Haemost 2023; (e-pub ahead of print). DOI: 10.1055/s-0043-1776900.
• 11 Chao TF, Joung B, Takahashi Y. et al. 2021 focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation: executive summary. Thromb Haemost 2022; 122 (01) 20-47
• 12 Schenker C, Stalder O, Méan M. et al. Bleeding risk in elderly patients with venous thromboembolism who would have been excluded from anticoagulation trials. Thromb Haemost 2023; 123 (04) 427-437
• 13 Li Z, Xu W, Wang L. et al. Risk of bleeding in liver cirrhosis receiving direct oral anticoagulants: a systematic review and meta-analysis. Thromb Haemost 2023; 123 (11) 1072-1088
• 14 Iding AFJ, Kremers BMM, Pallares Robles A, Ten Cate H, Ten Cate-Hoek AJ. Residual venous obstruction as an indicator of clinical outcomes following deep vein thrombosis: a management study. Thromb Haemost 2023; 123 (08) 763-772
• 15 Becattini C, Agnelli G. Residual thrombosis: still relevant in the direct oral anticoagulant (DOAC) era?. Thromb Haemost 2023; 123 (08) 747-749
• 16 Ivany E, Lotto RR, Lip GYH, Lane DA. Managing uncertainty: physicians' decision making for stroke prevention for patients with atrial fibrillation and intracerebral hemorrhage. Thromb Haemost 2022; 122 (09) 1603-1611
• 17 Gorman J, Candeloro M, Schulman S. Anticoagulant management and outcomes in nontraumatic intracranial hemorrhage complicated by venous thromboembolism: a retrospective chart review. Thromb Haemost 2023; 123 (10) 966-975
• 18 Milling Jr TJ. The hard bargain of anticoagulation after intracranial hemorrhage, in the setting of venous thromboembolism: between a rock and a hard place. Thromb Haemost 2023; 123 (10) 976-977
• 19 Lasne D, Toussaint-Hacquard M, Delassasseigne C. et al. Factors influencing anti-Xa assays: a multicenter prospective study in critically ill and noncritically ill patients receiving unfractionated heparin. Thromb Haemost 2023; 123 (12) 1105-1115
• 20 Yoon D, Jeong HE, Choi S, Shin JY, Bang SM. Dynamic patterns and persistence of anticoagulation therapy in patients with venous thromboembolism in South Korea: a nationwide cohort study. Thromb Haemost 2023; (e-pub ahead of print). DOI: 10.1055/a-2107-0815.
• 21 Germini F, Chan NC. Patterns and persistence of anticoagulant use in the treatment of venous thromboembolism: insights from South Korea. Thromb Haemost 2023; (e-pub ahead of print). DOI: 10.1055/a-2131-7066.
• 22 Gorog DA, Gue YX, Chao TF. et al. Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: executive summary of a European and Asia-Pacific expert consensus paper. Thromb Haemost 2022; 122 (10) 1625-1652
• 23 Goto S, Goto S. Dual antiplatelet (DAPT) or dual pathway inhibition (DPI). Thromb Haemost 2023; (e-pub ahead of print). DOI: 10.1055/a-2191-7627.
• 24 Kim HK, Tantry US, Smith Jr SC. et al. The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease. Thromb Haemost 2021; 121 (04) 422-432
• 25 Gorog DA, Jeyalan V, Markides RIL, Navarese EP, Jeong YH, Farag M. Comparison of de-escalation of DAPT intensity or duration in East Asian and Western patients with ACS undergoing PCI: a systematic review and meta-analysis. Thromb Haemost 2023; 123 (08) 773-792
• 26 Ortega-Paz L, Franchi F, Rollini F. et al. Switching from dual antiplatelet therapy with aspirin plus a P2Y12 inhibitor to dual pathway inhibition with aspirin plus vascular-dose rivaroxaban: the Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) study. Thromb Haemost 2023 (e-pub ahead of print) DOI: 10.1055/a-2098-6639
• 27 Birocchi S, Rocchetti M, Minardi A, Podda GM, Squizzato A, Cattaneo M. Guided anti-P2Y12 therapy in patients undergoing PCI: three systematic reviews with meta-analyses of randomized controlled trials with homogeneous design. Thromb Haemost 2023; (e-pub ahead of print). DOI: 10.1055/a-2149-4344.
• 28 Landolina D, Ammirabile N, Capodanno D. Strategies for tailored antiplatelet therapy after percutaneous coronary intervention: unraveling complexities, embracing nuances. Thromb Haemost 2023
• 29 Stefanini L, Ruberto F, Curreli M. et al. Increased von Willebrand factor platelet-binding capacity is related to poor prognosis in COVID-19 patients. Thromb Haemost 2023; 123 (01) 118-122
• 30 Giannis D, Goldin M, Rahman H. et al. Risk factors for postdischarge major thromboembolism and mortality in hospitalized patients with COVID-19 with cardiovascular comorbidities: insights from the CORE-19 registry. Thromb Haemost 2023; 123 (11) 1089-1099
• 31 Rolling CC, Sowa MA, Wang TT. et al. P2Y12 inhibition suppresses proinflammatory platelet-monocyte interactions. Thromb Haemost 2023; 123 (02) 231-244
• 32 Talasaz AH, Sadeghipour P, Bakhshandeh H. et al. Atorvastatin versus placebo in ICU patients with COVID-19: ninety-day results of the INSPIRATION-S trial. Thromb Haemost 2023; 123 (07) 723-733
• 33 Tu W-J, Xu Y, Liu Y, Li J, Du J, Zhao J. Intravenous thrombolysis or medical management for minor strokes. Thromb Haemost 2023; 123 (07) 734-743
• 34 Cameron AC, Abdul-Rahim AH. The optimal management for people with acute stroke and minor deficits: intravenous thrombolysis or medical management?. Thromb Haemost 2023; 123 (07) 666-668
• 35 Duarte-Gamas L, Jácome F, Dias LR. et al. Catheter-directed thrombolysis protocols for deep venous thrombosis of the lower extremities-a systematic review and meta-analysis. Thromb Haemost 2023; (e-pub ahead of print). DOI: 10.1055/a-2106-3754.
• 36 Barnes GD, Obi AT. Catheter-directed thrombolysis for deep vein thrombosis: serving at break point. Thromb Haemost 2023; (e-pub ahead of print). DOI: 10.1055/s-0043-1776009.
• 37 Becattini C, Agnelli G, Maggioni AP. et al; COPE Investigators. Contemporary management and clinical course of acute pulmonary embolism: the COPE study. Thromb Haemost 2023; 123 (06) 613-626
• 38 Hwang HG, Lee JH, Bang SM. Incidence of pregnancy-associated venous thromboembolism: second nationwide study. Thromb Haemost 2023; 123 (09) 904-910
• 39 Tsai C-T, Chao T-F. Incidence and risk factors for pregnancy-associated venous thromboembolism: are there differences between east and west?. Thromb Haemost 2023; 123 (09) 911-912
• 40 Grandone E, Antonucci E, Colaizzo D. et al. Venous thromboembolism in women of childbearing age: insights from the START registry. Thromb Haemost 2023; 123 (11) 1060-1068
• 41 Xu K, Chan NC. Risk factors for venous thromboembolism in women of childbearing age. Thromb Haemost 2023; 123 (11) 1069-1071
• 42 Goualou M, Noumegni S, de Moreuil C. et al. Venous thromboembolism associated with assisted reproductive technology: a systematic review and meta-analysis. Thromb Haemost 2023; 123 (03) 283-294
• 43 Grandone E, Ageno W. The legacy of Edwards and Steptoe and the windy roads of assisted reproduction: where do we stand with venous thromboembolism?. Thromb Haemost 2023; 123 (03) 267-269
• 44 Corica B, Lobban T, True Hills M. et al. Sex as a risk factor for atrial fibrillation-related stroke. Thromb Haemost 2023; (e-pub ahead of print). DOI: 10.1055/s-0043-1776394.
• 45 Frischmuth T, Tøndel BG, Brækkan SK. et al. The risk of incident venous thromboembolism attributed to overweight and obesity: the Tromsø Study. Thromb Haemost 2023 (e-pub ahead of print) DOI: 10.1055/s-0043-1772212
• 46 Wang J, Tan J, Hua L, Sheng Q, Huang X, Liu P. Genetic predisposition of both waist circumference and hip circumference increased the risk of venous thromboembolism. Thromb Haemost 2023; 123 (03) 347-361
• 47 Gaugler JO, Righini M, Robert-Ebadi H. et al. Obesity as a predictor for pulmonary embolism and performance of the age-adjusted D-dimer strategy in obese patients with suspected pulmonary embolism. Thromb Haemost 2023; (e-pub ahead of print). DOI: 10.1055/s-0043-57018.
• 48 Goldhaber SZ. Obesity and pulmonary embolism: can we dismantle the “obesity paradox”. Thromb Haemost 2023
• 49 Martin KA, Zakai NA. Venous thromboembolism and obesity: moving toward a better understanding of the population-attributable risk. Thromb Haemost 2023; (e-pub ahead of print). DOI: 10.1055/s-0043-1776010.
• 50 Roberge G, Samson C, Le Gal G, Calabrino A. Prolonged fasting as a cause of deep vein thrombosis: a case report. TH Open 2023; 7 (02) e94-e96
• 51 McIntyre W, Collaborators ASAE. AF SCREEN and AFFECT-EU Collaborators. Protocol for a systematic review and individual participant data meta-analysis of randomized trials of screening for atrial fibrillation to prevent stroke. Thromb Haemost 2023; 123 (03) 366-376
• 52 Ryu J-C, Bae J-H, Ha SH. et al. Hypercoagulability on thromboelastography can predict the functional outcomes in patients with acute ischemic stroke. Thromb Haemost 2023; 123 (12) 1180-1186
• 53 Paciaroni M. Hypercoagulability state in predicting severe functional outcome in patients with acute ischemic stroke: cause, consequence, or both?. Thromb Haemost 2023; 123 (12) 1187-1189
• 54 le Sève JD, Guédon AF, Bordenave S. et al. Risk factors of venous thromboembolic disease in cancer patients treated with immune checkpoint inhibitor. Thromb Haemost 2023; 123 (11) 1049-1056
• 55 Khorana AA. Immune checkpoint inhibitors and venous thromboembolism: the more things change…. Thromb Haemost 2023; 123 (11) 1057-1059
• 56 McBane Ii RD, Vlazny DT, Houghton D. et al. Survival implications of thrombus recurrence or bleeding in cancer patients receiving anticoagulation for venous thromboembolism treatment. Thromb Haemost 2023; 123 (05) 535-544
• 57 Xu K, Chan NC. Recurrent thrombosis and bleeding in patients with cancer-associated venous thromboembolism receiving anticoagulation: are these modifiable risk factors for mortality?. Thromb Haemost 2023; 123 (05) 487-489
• 58 Cohen AT, Wallenhorst C, Choudhuri S, Nassar A, Pollock KG, Martinez C. A novel risk prediction score for clinically significant bleeding in patients anticoagulated for venous thromboembolism with active cancer. Thromb Haemost 2023; (e-pub ahead of print). DOI: 10.1055/a-2145-7238.
• 59 Roldán V, Soler-Espejo E, Marin F. Predicting bleeding in cancer-associated venous thromboembolism: another milestone achieved. Thromb Haemost 2023; (e-pub ahead of print). DOI: 10.1055/s-0043-1775582.
• 60 Rønnow Sand J, Troelsen FS, Nagy D. et al. Increased cancer risk in patients with kidney disease and venous thromboembolism: a population-based cohort study. Thromb Haemost 2023; 123 (12) 1165-1176
• 61 Konstantinides SV. Kidney disease and cancer risk in patients with venous thromboembolism: what does it mean for clinical practice?. Thromb Haemost 2023; 123 (12) 1177-1179
• 62 Caroti KS, Becattini C, Carrier M. et al. Rivaroxaban versus apixaban for treatment of cancer-associated venous thromboembolism in patients at lower risk of bleeding. TH Open 2023; 7 (03) e206-e216
• 63 Sigüenza P, López-Núñez JJ, Falgá C. et al; RIETE Investigators. Enoxaparin for the long-term therapy of venous thromboembolism in patients with cancer and renal insufficiency. Thromb Haemost 2023; (e-pub ahead of print). DOI: 10.1055/a-2191-7510.
• 64 Trzepizur W, Gervès-Pinquié C, Heudes B. et al; Pays de la Loire Cohort Study Group. Sleep apnea and incident unprovoked venous thromboembolism: data from the Pays de la Loire sleep cohort. Thromb Haemost 2023; 123 (04) 393-401
• 65 Bikdeli B, Lo Y-C, Khairani CD. et al. Developing validated tools to identify pulmonary embolism in electronic databases: rationale and design of the PE-EHR+ study. Thromb Haemost 2023; 123 (06) 649-662
• 66 Squizzato A, Venturini A, Pelitti V. et al. Diagnostic accuracy of V/Q and Q SPECT/CT in patients with suspected acute pulmonary embolism: a systematic review and meta-analysis. Thromb Haemost 2023; 123 (07) 700-713
• 67 Konstantinides S. Modern lung scintigraphy techniques for optimizing the diagnosis of pulmonary embolism: great expectations still awaiting to be met. Thromb Haemost 2023; 123 (07) 663-665
• 68 Pedersen OB, Grove EL, Nissen PH. et al. Expression of microRNA predicts cardiovascular events in patients with stable coronary artery disease. Thromb Haemost 2023; 123 (03) 307-316
• 69 Liu X, Li X, Xiong S. et al. Neutrophil extracellular traps: potential prothrombotic state markers and therapeutic targets for atrial fibrillation. Thromb Haemost 2023; (e-pub ahead of print). DOI: 10.1055/s-0043-1774310.
• 70 Wang G, Abrams ST, Toh C-H. Are NETs a novel, exciting, thrombosis risk marker?. Thromb Haemost 2023; (e-pub ahead of print). DOI: 10.1055/a-2187-0645.
• 71 Lahu S, Adler K, Mayer K. et al. Plasma soluble glycoprotein VI, platelet function, bleeding, and ischemic events in patients undergoing elective percutaneous coronary intervention. Thromb Haemost 2023; (e-pub ahead of print). DOI: 10.1055/s-0043-1772221.
• 72 Harm T, Frey M, Dittrich K. et al. Statin treatment is associated with alterations in the platelet lipidome. Thromb Haemost 2023; 123 (06) 585-596
• 73 Goto S, Goto S. Statin treatment and the alterations in the platelet lipidome: what is the impact of lipid profile on thrombosis?. Thromb Haemost 2023; 123 (06) 573-575
• 74 Chen D, Zhao Z, Liu P. et al. Adventitial vasa vasorum neovascularization in femoral artery of type 2 diabetic patients with macroangiopathy is associated with macrophages and lymphocytes as well as the occurrence of cardiovascular events. Thromb Haemost 2023; 123 (10) 989-998
• 75 Badimon L, Arderiu G. Atherosclerotic plaque VASA vasorum in diabetic macroangiopathy: WHEN IS important, but also HOW IS needed. Thromb Haemost 2023; 123 (10) 999-1002
• 76 Bianchini M, Möller-Ramon Z, Weber C, Megens RTA, Duchêne J. Short-term western diet causes rapid and lasting alterations of bone marrow physiology. Thromb Haemost 2023; 123 (11) 1100-1104
• 77 Sachetto ATA, Mackman N. Monocyte tissue factor expression: lipopolysaccharide induction and roles in pathological activation of coagulation. Thromb Haemost 2023; 123 (11) 1017-1033
• 78 Bongiovanni D, Novelli L, Condello F. et al. Reticulated platelets predict cardiovascular death and adverse events in coronary artery disease: a systematic review and meta-analysis. Thromb Haemost 2023; (e-pub ahead of print). DOI: 10.1055/s-0043-1773763.
• 79 Esteve-Pastor MA, Soler-Espejo E, Marín F. Reticulated platelets: a promising prognosis marker in cardiovascular diseases. Thromb Haemost 2023; (e-pub ahead of print). DOI: 10.1055/a-2170-1892.
• 80 Kawano T, Hisada Y, Grover SP. et al. Decreased platelet reactivity and function in a mouse model of human pancreatic cancer. Thromb Haemost 2023; 123 (05) 501-509
• 81 Gui X, Chu X, Du Y. et al. Impaired platelet function and thrombus formation in PDE5A-deficient mice. Thromb Haemost 2023; 123 (02) 207-218
• 82 Seidizadeh O, Ciavarella A, Baronciani L. et al. Clinical and laboratory presentation and underlying mechanism in patients with Low VWF. Thromb Haemost 2023; (e-pub ahead of print). DOI: 10.1055/a-2186-6362.
• 83 Nagy Z, Nieswandt B. PDE5A: key enzyme to overcome platelet inhibition. Thromb Haemost 2023; 123 (02) 131-132
• 84 Bourne JH, Smith CW, Jooss NJ. et al. CLEC-2 supports platelet aggregation in mouse but not human blood at arterial shear. Thromb Haemost 2022; 122 (12) 1988-2000
• 85 McFadyen JD, Mangin PH, Peter K. Of mice and man: the unwinding of CLEC-2 as an antithrombotic target?. Thromb Haemost 2022; 122 (12) 1963-1965
• 86 Machado SK, Peil H, Kraushaar T. et al. Modulation of extravascular binding of recombinant factor IX impacts the duration of efficacy in mouse models. Thromb Haemost 2023; 123 (08) 751-762
• 87 Pilch J, Knowles LM. Extravascular binding of coagulation factor IX gives hemostasis a boost. Thromb Haemost 2023; 123 (08) 750
• 88 Souri M, Yokoyama C, Osaki T, Ichinose A. Antibodies against noncatalytic B subunit of factor XIII inhibit activation of factor XIII and fibrin crosslinking. Thromb Haemost 2023; 123 (09) 841-854
• 89 Katona É. Functional consequences of antibodies against noncatalytic B Subunit of factor XIII. Thromb Haemost 2023; 123 (09) 855